Moreover, it has been suggested that chronic alterations in glucose and IGF-1 levels are risk factors for bone fragility during diabetes, which may lead to bone remodeling and impaired formation, which could be alleviated by several anti-diabetic medications [6,7,8]. The gene discussed is IGF1; the disease is diabetes mellitus.